- Home
- PETZ vs CDT Comparison
PETZ vs CDT Comparison
Compare PETZ & CDT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PETZ
- CDT
- Stock Information
- Founded
- PETZ 2002
- CDT 2019
- Country
- PETZ China
- CDT United States
- Employees
- PETZ N/A
- CDT N/A
- Industry
- PETZ Steel/Iron Ore
- CDT Biotechnology: Pharmaceutical Preparations
- Sector
- PETZ Industrials
- CDT Health Care
- Exchange
- PETZ Nasdaq
- CDT Nasdaq
- Market Cap
- PETZ 12.9M
- CDT 11.1M
- IPO Year
- PETZ 2017
- CDT N/A
- Fundamental
- Price
- PETZ $1.15
- CDT $1.15
- Analyst Decision
- PETZ
- CDT
- Analyst Count
- PETZ 0
- CDT 0
- Target Price
- PETZ N/A
- CDT N/A
- AVG Volume (30 Days)
- PETZ 5.0K
- CDT 8.8M
- Earning Date
- PETZ 12-17-2024
- CDT 03-04-2025
- Dividend Yield
- PETZ N/A
- CDT N/A
- EPS Growth
- PETZ N/A
- CDT N/A
- EPS
- PETZ N/A
- CDT N/A
- Revenue
- PETZ $3,278,453.00
- CDT N/A
- Revenue This Year
- PETZ N/A
- CDT N/A
- Revenue Next Year
- PETZ N/A
- CDT N/A
- P/E Ratio
- PETZ N/A
- CDT N/A
- Revenue Growth
- PETZ 2.46
- CDT N/A
- 52 Week Low
- PETZ $1.01
- CDT $1.13
- 52 Week High
- PETZ $1.74
- CDT $392.00
- Technical
- Relative Strength Index (RSI)
- PETZ 44.66
- CDT 31.53
- Support Level
- PETZ $1.13
- CDT $1.60
- Resistance Level
- PETZ $1.23
- CDT $3.70
- Average True Range (ATR)
- PETZ 0.06
- CDT 0.44
- MACD
- PETZ -0.00
- CDT 0.09
- Stochastic Oscillator
- PETZ 16.67
- CDT 0.78
About PETZ TDH Holdings Inc.
TDH Holdings Inc is engaged in the business of manufacturing and selling of petfood and restaurant operations. The company has two operating segments which include Petfood sales and Restaurant business. It has a focus on the Restaurant business segment and generates the majority of its revenue.
About CDT Conduit Pharmaceuticals Inc.
Conduit Pharmaceuticals Inc is a clinical-stage specialty biopharmaceutical company that was formed to facilitate the development and commercialization of clinical assets that have not been or are not being, prioritized by leading biopharmaceutical companies in order to develop pharmaceutical products that meet the unmet medical needs of patients. The Company's current development pipeline includes a glucokinase activator, which is Phase II ready in autoimmune diseases including uveitis, Hashimoto's Thyroiditis, preterm labor and renal transplant rejection. The Company's development pipeline also includes a potent, irreversible inhibitor of human Myeloperoxidase (MPO) that has the potential to treat idiopathic male infertility.